Breast cancer patients with cardiac disease are usually excluded from clinical trials of high-dose chemotherapy. We treated 52 patients with inflammatory and/or metastatic disease with sequential high-dose melphalan and stem cell rescue followed by high-dose thiotepa and stem cell rescue. Stem cells were mobilized with cyclophosphamide and/or paclitaxel and filgrastim. Left ventricular ejection fraction (LVEF) was measured by equilibrium radionuclide angiocardiography (ERNA) at baseline, after each course of chemotherapy and 4 weeks after completing both transplants. The mean absolute decrease in LVEF after the two transplants was 3.6% (P ‫؍‬ 0.008 for the comparison with baseline LVEF), and most of this drop (؊2.5%, P ‫؍‬ 0.007) occurred after mobilization. Unexpectedly, paclitaxel was associated with a mean absolute decrease in LVEF of 3.4% (P ‫؍‬ 0.032, n ‫؍‬ 19), cyclophosphamide alone was not associated with a significant change in LVEF (؊1.3%, P ‫؍‬ 0.23), but mobilization with sequential paclitaxel and cyclophosphamide resulted in a mean absolute drop of 4.9% in LVEF (P ‫؍‬ 0.009). Twelve patients were found to have a reduced LVEF (Ͻ50%) at least once during treatment and had a mean absolute decrease in LVEF of 10% (P ‫؍‬ 0.008) from baseline, compared with a drop of only 1.8% (P ‫؍‬ 0.176) in the patients without impaired LV function. Although two of these 12 patients developed symptomatic heart failure, their cardiac symptoms were easily treated and there were no cardiac deaths. We conclude that our protocol has acceptable cardiac toxicity and breast cancer patients with impaired LV function should not be denied high-dose chemotherapy if otherwise indicated. Bone Marrow Transplantation (2000) 26, 133-139.
exposure, with its associated risk of dose-dependent cardiotoxicity, is almost universal in these patients. The incidence of acute doxorubicin-induced cardiomyopathy rises from 0.14% at a cumulative dose of less than 400 mg/m 2 body surface area to 7% at a cumulative dose of 550 mg/m 2 . 1,2 Other risk factors for doxorubicin-induced cardiomyopathy include higher rates of drug administration, mediastinal radiation, pre-existing heart disease and hypertension. [1] [2] [3] Late-onset symptomatic congestive heart failure, occurring more than 1 year, and up to 12-14 years after completing therapy, has been reported in approximately 5% of patients treated with doxorubicin. 4, 5 Echocardiographic abnormalities are detected in 18-65% of asymptomatic patients followed for up to 15 years after doxorubicin therapy.
Cyclophosphamide and paclitaxel are two other cardiotoxic agents commonly used in breast cancer patients. Cyclophosphamide is not cardiotoxic at conventional doses 6 but may cause myocardial damage at the higher doses used in transplantation, [6] [7] [8] [9] [10] especially in patients with prior cardiac disease. 8 Paclitaxel may cause rhythm disturbances and ischemia, but has not previously been shown to cause cardiomyopathy. 11 The number of breast cancer patients who are ineligible for high-dose chemotherapy and autologous transplant because of cardiac disease is unknown. A recent study found that two of 171 patients who received standard adjuvant combination chemotherapy (cyclophosphamide, methotrexate and flourouracil or anthracycline-containing regimens) did not meet high-dose chemotherapy criteria because of cardiac disease. 12 The incidence of cardiac disease in patients who have been treated for metastatic disease is likely to be much higher, and there are no published data on the feasibility of treating these patients with highdose chemotherapy.
Between May 1994 and June 1998 we treated 56 patients suffering from inflammatory and/or metastatic breast cancer with high-dose chemotherapy and peripheral blood stem cell support. Four of these patients were excluded from this study: in three patients serial measurements of LVEF were not performed, and one patient was transplanted on a different protocol. Thus, in the present report we include the 52 patients for whom we have at least three serial measurements of cardiac function (Table 1) . Twelve of these patients either had impaired cardiac function (LVEF Ͻ50%) before starting high-dose chemotherapy, or developed it during treatment. The purpose of this study is to describe the clinical course and management of trans- plantation in these patients and to report on the cardiac toxicity of our high-dose chemotherapy regimen for breast cancer.
Methods

Clinical protocol
Patients with inflammatory and/or metastatic breast cancer were eligible for high-dose chemotherapy with stem cell support if they had had a partial or complete response to conventional-dose chemotherapy, did not have brain metastasis, had a Karnofsky performance status of 80% or more, and did not have significant pulmonary, hepatic or renal disease. Patients with inflammatory breast cancer were treated with high-dose chemotherapy if significant disease was discovered at surgery following neoadjuvant chemotherapy with an anthracycline-containing regimen. We used two protocols to mobilize stem cells into the peripheral blood (see Figure 1) : patients who had received prior treatment with paclitaxel were mobilized twice, once with paclitaxel 225-300 mg/m 2 over 3 or 24 h 13 and filgrastim 5 g/kg and 1 month later with cyclophosphamide 5 g/m 2 and filgrastim 5 g/kg. Patients who had not received paclitaxel before undergoing transplantation were mobilized only with cyclophosphamide/filgrastim at the above doses. Four weeks after mobilizing chemotherapy, patients received melphalan 140 mg/m 2 divided into two doses followed by stem cell reinfusion, and 3-4 weeks later they received thiotepa 900 mg/m 2 divided into two doses followed again by stem cell reinfusion.
Both mobilization protocols and the transplant protocol were approved by the Human Investigation Committee of Yale University. However, patients who were not eligible for the protocols because of impaired cardiac function underwent transplant according to local practice standards which favored high-dose chemotherapy for patients with chemotherapy-responsive inflammatory and/or metastatic breast cancer. Patients on protocol who developed a reduced LVEF were taken off protocol but in most cases completed both cycles of high-dose chemotherapy. Our report includes a retrospective analysis of all the patients treated with high-dose chemotherapy for breast cancer, both on and off protocol, for whom we have adequate cardiac data.
Cardiac evaluation
Baseline cardiac function was evaluated by history, physical examination, resting electrocardiograms, and equilibrium radionuclide angiocardiography (ERNA or MUGA). An ERNA was subsequently obtained for each patient a few days before each dose of chemotherapy and 4 weeks after completing the transplant protocol. Of the 216 ERNAs performed in our 52 patients, 187 (86%) were performed at the Yale-New Haven Hospital Cardiovascular Nuclear Imaging Laboratory using a standard protocol specific to our center.
14 A study of the reproducibility of ERNAs performed at Yale-New Haven Hospital concluded that 'in 95% of cases, repeat quantitative radionuclide assessments of LVEF can be expected to be within a 2% to 4% range'. 15 In the event that the LVEF was less than 50%, and/or the patient had signs or symptoms of cardiac disease, she was evaluated by a cardiologist (FAL) and additional cardiac studies were obtained at his discretion.
Statistical analysis
The two-sided t-test was used to compare independent groups of patients (with and without impaired LV function, treated and not treated with paclitaxel). The two-sided paired t-test or the non-parametric Wilcoxon signed rank test were used to compare the changes in LVEF in patients during treatment. A P value of less than 0.05 was considered significant.
Results
Of the 52 women in this study, 49 completed both courses of high-dose chemotherapy and three received high-dose melphalan only. One of the latter three patients refused the thiotepa chemotherapy, one patient had not mobilized enough stem cells for a second transplant, and in one patient therapy was stopped because of disease progression. Fifty of the 52 women had been treated with doxorubicin, with an interval of 1 to 72 months (median 2 months) between their last dose of doxorubicin and the first dose of mobilizing chemotherapy. The median cumulative dose of doxorubicin was 300 mg/m 2 (range 50-687 mg/m 2 ). Among the patients who completed the first course of highdose chemotherapy (melphalan), the mean absolute decrease in LVEF (LVEF at baseline before mobilizing chemotherapy subtracted from LVEF 4 weeks after melphalan chemotherapy) was 1.94% (data complete on 50 patients, P ϭ 0.048). Among the patients who completed both transplants, the mean absolute decrease in the LVEF (LVEF at baseline before mobilizing chemotherapy subtracted from LVEF 4 weeks after thiotepa chemotherapy) was 3.6%, with a range of Ϫ25% to ϩ15% (data complete on 41 patients, P ϭ 0.008). Most of this drop (2.5%, P ϭ 0.007) occurred after cyclophosphamide mobilization (Table 1) .
We then compared patients who had received prior treatment with paclitaxel, and therefore underwent sequential paclitaxel and cyclophosphamide mobilization (n ϭ 19), with those who had not (n ϭ 33), and therefore were mobilized with cyclophosphamide alone. The two groups of patients did not differ with regard to age, cumulative doxorubicin dose or baseline LVEF. The patients who had received prior treatment with paclitaxel did have a significantly longer interval between the completion of doxorubicin chemotherapy and transplant (3.5 vs 25.1 months, P ϭ 0.0001), as most of these patients had received doxorubicin in the adjuvant setting and paclitaxel for metastatic disease. In these patients there was a mean absolute drop of 3.4% in LVEF after paclitaxel mobilization (P ϭ 0.032), which did not occur in patients who received cyclophosphamide Bone Marrow Transplantation alone for mobilization (a mean absolute drop of 1.3%, P ϭ 0.23). Patients who received both paclitaxel and cyclophosphamide sequentially for mobilization sustained an absolute drop of 4.9% from baseline LVEF (P ϭ 0.009). There appeared to be some recovery of cardiac function in the subsequent months in this latter group despite administration of high-dose chemotherapy with melphalan and thiotepa, because 1 month after completing the two cycles of high-dose alkylating agents both groups of patients had experienced a similar mean absolute drop in LVEF: 3.4% in the paclitaxel/cyclophosphamide group (P ϭ 0.049) and 3.8% in the cyclophosphamide alone group (P ϭ 0.055) ( Table 1) .
Twelve of the 52 patients (Table 2) were found to have a LVEF below 50% on at least one occasion during treatment. Two patients in this group (Nos 4 and 12) had received radiation therapy to the chest, a known risk factor for chemotherapy-induced cardiotoxicity. 3 One of the 12 patients (No. 8) had a history of treated hypertension, whereas the rest had no history of cardiovascular disease. Four of these patients (Nos 2, 7, 9 and 11) had a LVEF of less than 50% before beginning their mobilizing regimen. Of these, only patient No. 7 had a severely decreased LVEF (33%) but she had not tolerated treatment with either digoxin or captopril, and was asymptomatic and not receiving any cardiac medications at the time of enrollment. The other eight women developed a decrease in LVEF during or after treatment. In two patients (Nos 1 and 3) a mildly decreased LVEF was found during treatment, chemotherapy was delayed, and a repeat ERNA 1 week later showed an improvement in the LVEF to above 50%. In one patient (No. 5) LVEF was 67-72% throughout therapy but 4 weeks after completing the transplant protocol it was found to be 42% on two separate occasions. Three patients (Nos 4, 7 and 10) underwent a cardiac echocardiogram to further characterize their heart function and were found to have no valvular disease or regional wall motion abnormalities. Patient No. 8 had hypertension, and underwent an adenosine sestamibi myocardial perfusion scan after she was found to have a reduced LVEF, which did not demonstrate ischemia.
These 12 patients did not differ from the 40 patients who did not develop impaired left ventricular function with regard to age (42 vs 45 years, respectively), mean cumulative dose of doxorubicin (337 vs 270 mg/m 2 , P ϭ 0.12), interval between completing doxorubicin treatment and transplant (14 vs 10 months) or prior treatment with paclitaxel (4/12 compared with 15/40). As expected, the mean baseline LVEF of this group was lower (52% vs 63%) and they had a mean absolute decrease in LVEF of 10% during therapy (P ϭ 0.008 for the difference between baseline LVEF and LVEF post thiotepa), while the rest of the patients sustained a non-significant mean decrease of only 1.8% (P ϭ 0.176). In both groups of patients, the most significant single drop in EF occurred after cyclophosphamide therapy, with a decrease of 4.1% (P ϭ 0.026) in the patients with impaired left ventricular function and 2.1% in the patients without (P ϭ 0.054) (Figure 2) .
Eleven of the 12 patients had at least one episode of febrile neutropenia during therapy, 11 required packed red blood cell transfusions (2-6 units) and all patients required platelet transfusions. However, despite these cardiovascular stressors, only two patients developed symptomatic heart failure (Nos 7 and 8), both of whom had a LVEF below 40% (Table 2 ). Patient No. 10 had an episode of supraventricular tachycardia during rapid flushing of her central line. She underwent a cardiac echocardiogram which showed no valvular disease or regional wall motion abnormalities and was evaluated by our cardiologist, who concluded that the arrythmia was not secondary to her cardiomyopathy. There were no other cardiac events and no cardiac mortality in the 52 patients studied. At a median follow-up of 26 months, 28 patients (54%) have died, 5/12 (42%) of the patients with an impaired LVEF and 23/40 (57%) of the patients with a normal LVEF.
Discussion
We describe the cardiac toxicity of high-dose chemotherapy with autologous transplant in 52 patients with breast cancer, including 12 women who successfully completed at least one course of high-dose chemotherapy and peripheral blood stem cell transplant despite reduced LVEF.
The reasons for excluding patients with reduced LVEF from transplant protocols are two-fold -concern regarding their tolerance of the non-cardiac toxicity, and the possibility of additional acute and/or long-term cardiac toxicity from the high-dose chemotherapy. Most of our patients with impaired cardiac function easily tolerated the hydration necessary for the administration of chemotherapy and stem cell reinfusions, the leukapheresis sessions, neutropenic sepsis, episodic anemia and blood transfusions. The two patients who developed symptomatic pulmonary congestion were easily managed with diuretics and afterload reduction. The reduced morbidity of newer transplant regimens such as ours is at least partially due to the use of peripheral blood and not bone marrow as the source of stem cells. This abolishes the need for general anesthesia to harvest stem cells and results in quicker hematopoietic reconstitution, lower transfusion needs and fewer days on intravenous antibiotics. 16 
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There are few studies describing the short and long-term cardiac toxicity of autologous transplant in women with breast cancer. In a multi-center Australian study, Basser et al 17 reported the cardiac toxicity of three cycles of highdose epirubicin and cyclophosphamide followed by autologous stem cell transplant in 99 women with early stage, poor prognosis breast cancer. In contrast to our study, all women had a LVEF of 50% or above before receiving their first cycle of high-dose chemotherapy. Patients were followed by serial ERNAs before each chemotherapy cycle, every 3 months in the first year after completing treatment, and then yearly. They found that 35 of the 99 patients had at least one measurement of LVEF that was below normal during the follow-up period, although 20 of these 35 patients subsequently had normal LVEF on further followup. Nineteen of the 99 patients developed a reduced LVEF during the treatment period but completed all three chemotherapy cycles. One patient died of acute myocardial necrosis after the third cycle of chemotherapy and two others developed severe progressive heart failure 2 years after completing chemotherapy. The mean absolute decrease in LVEF after the three high-dose chemotherapy cycles in this study was 6.0%.
de Graaf et al 18 reported 86 patients with locally advanced or metastatic breast cancer treated with doxorubicin or epirubicin-based induction chemotherapy and cyclophosphamide or mitoxantrone-based ablative chemotherapy. All patients had normal cardiac function before starting treatment. One patient died of cardiotoxicity 3 months after ablative chemotherapy, and of the 27 patients surviving at least 1 year post transplant, one developed severe heart failure 2 weeks after a second transplant. However, the authors do not report how frequently these patients were monitored for cardiac disease during treatment.
Several other studies have suggested that non-breast cancer patients with reduced LVEF may tolerate transplantation. Carlson et al 19 studied cardiac function in 111 patients with predominantly hematologic malignancies who survived disease-free for more than 6 months after autologous bone marrow transplant. Patients received a variety of conditioning regimens including combinations of total body irradiation, cyclophosphamide, melphalan, BCNU, etoposide, cytosine arabinoside and busulfan. Eleven patients had pre-transplant LVEF Ͻ 50% but did not have subsequent cardiac deterioration. In this study only the patients with lymphoma transplanted in second or higher remission suffered a significant decrease in their LVEF post transplant. In a small study by Kakavas et al, 20 six patients with initial LVEF Ͻ 50% were treated with enalapril with a significant improvement in their cardiac function, and were able to complete allogeneic or autologous transplants. In a study by Ghielmini et al 21 20 lymphoma patients were treated with a sequence of cyclophosphamide, methotrexate, etoposide, mitoxantrone and melphalan, each at a high dose, with the melphalan followed by autologous peripheral stem cell rescue. Cardiac function was monitored by echocardiography. All patients had an LVEF greater than 50% before enrollment, but the mean absolute decrease in LVEF was only 3% 6 months after completing therapy, suggesting that the treatment protocol would be well tolerated by patients with prior cardiac disease.
The agents with known cardiotoxicity in our transplant protocol are paclitaxel and cyclophosphamide, which were both used to mobilize stem cells into peripheral blood. Paclitaxel's main cardiac toxicity is bradycardia and other arrhythmias, which are thought to result, at least in part, from histamine release caused by Cremophor EL, the formulation vehicle. 11 Paclitaxel only rarely causes cardiomyopathy when administered as a single agent, 22 but it enhances the cardiotoxicity of doxorubicin when given in combination. 23, 24 Cyclophosphamide is cardiotoxic at high doses, causing hemorrhagic myocardial necrosis and pericarditis which may be lethal. 8 Its toxicity is dose-dependent 10 and is thought to be mediated by an increase in free oxygen radicals from its metabolite phosphoramide mustard. 9 None of our patients developed acute cyclophosphamide cardiotoxicity despite using 5 g/m 2 cyclophosphamide to mobilize stem cells, and there was no cardiac mortality in our study. This may be due to several factors: (1) we used only one course of high-dose cyclophosphamide in our protocol; (2) paclitaxel was used instead of cyclophosphamide in the one patient who had an LVEF below 40% before mobilization; (3) the other chemotherapeutic agents in our protocol have low cardiac toxicity; and (4) cyclophosphamide was dosed based on adjusted body surface area and not body weight. 10 In our patients, we found a small but significant drop in LVEF after paclitaxel therapy and after paclitaxel/highdose cyclophosphamide sequential therapy but not after high-dose cyclophosphamide alone. Although our sample size is small, these results suggest that paclitaxel may cause sub-clinical cardiac injury which predisposes patients to further damage from cardiotoxic agents such as high-dose cyclophosphamide. Melphalan and thiotepa have not been shown to cause cardiac damage even at the high doses used for transplant and did not seem to contribute to cardiac disease in our study.
All our patients were monitored with ERNAs performed after every stage of therapy. Quantitative radionuclide angiocardiography has been established as the preferred method of monitoring patients treated with anthracyclines [25] [26] [27] and can identify patients at a high risk of developing significant cardiac toxicity. In a retrospective study, Schwartz et al 26 found that in patients treated with doxorubicin, a decline of 10% or more in absolute LVEF to a value of 50% or less, as determined by ERNA, identified patients who subsequently developed clinical congestive heart failure if therapy with doxorubicin was continued. In a study performed in our institution, 15 ERNA was found to be more reproducible than echocardiography, with the latter associated with potentially clinically relevant differences in 8-26% of cases on repeat analysis.
Our experience suggests that patients with reduced LVEF can undergo therapy with high-dose chemotherapy and autologous stem cell support if highly cardiotoxic agents are avoided and patients receive the appropriate cardiac monitoring and therapy. Further studies are needed to determine the short-and long-term cardiotoxicity of the many high-dose chemotherapeutic protocols currently in use, and whether the availability of cardioprotectants such as dexrazoxane will diminish the prevalence of cardiac disease in transplant candidates.
